Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib

Michael Mian; Norbert Pescosta; Stefania Badiali; Paola Cristina Cappelletto; Luigi Marcheselli; Stefano Luminari; Francesca Patriarca; Renato Zambello; Anna Pascarella; Giuseppe Tagariello; Alessandra Marabese; Patrizia Mondello; Atto Billio; Sergio Cortelazzo

doi:10.1111/bjh.15645

Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib

Michael Mian, Norbert Pescosta, Stefania Badiali, Paola Cristina Cappelletto, Luigi Marcheselli, Stefano Luminari, Francesca Patriarca, Renato Zambello, Anna Pascarella, Giuseppe Tagariello, Alessandra Marabese, Patrizia Mondello, Atto Billio, Sergio Cortelazzo

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.15645
Publication status	E-pub ahead of print - Nov 26 2018

Access to Document

10.1111/bjh.15645

Cite this

Mian, M., Pescosta, N., Badiali, S., Cappelletto, P. C., Marcheselli, L., Luminari, S., Patriarca, F., Zambello, R., Pascarella, A., Tagariello, G., Marabese, A., Mondello, P., Billio, A., & Cortelazzo, S. (2018). Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. British Journal of Haematology. https://doi.org/10.1111/bjh.15645

Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. / Mian, Michael; Pescosta, Norbert; Badiali, Stefania et al.

In: British Journal of Haematology, 26.11.2018.

Research output: Contribution to journal › Article › peer-review

Mian, M, Pescosta, N, Badiali, S, Cappelletto, PC, Marcheselli, L, Luminari, S, Patriarca, F, Zambello, R, Pascarella, A, Tagariello, G, Marabese, A, Mondello, P, Billio, A & Cortelazzo, S 2018, 'Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib', British Journal of Haematology. https://doi.org/10.1111/bjh.15645

@article{d9432647bebd4d42b76a3c22ac11b5f7,

title = "Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib",

author = "Michael Mian and Norbert Pescosta and Stefania Badiali and Cappelletto, {Paola Cristina} and Luigi Marcheselli and Stefano Luminari and Francesca Patriarca and Renato Zambello and Anna Pascarella and Giuseppe Tagariello and Alessandra Marabese and Patrizia Mondello and Atto Billio and Sergio Cortelazzo",

year = "2018",

month = nov,

day = "26",

doi = "10.1111/bjh.15645",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons, Ltd (10.1111)",

}

TY - JOUR

T1 - Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib

AU - Mian, Michael

AU - Pescosta, Norbert

AU - Badiali, Stefania

AU - Cappelletto, Paola Cristina

AU - Marcheselli, Luigi

AU - Luminari, Stefano

AU - Patriarca, Francesca

AU - Zambello, Renato

AU - Pascarella, Anna

AU - Tagariello, Giuseppe

AU - Marabese, Alessandra

AU - Mondello, Patrizia

AU - Billio, Atto

AU - Cortelazzo, Sergio

PY - 2018/11/26

Y1 - 2018/11/26

U2 - 10.1111/bjh.15645

DO - 10.1111/bjh.15645

M3 - Article

C2 - 30478966

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -